Sanofi, one of the three major insulin makers in the US, has announced a 78% reduction in the list price of its most widely prescribed insulin, Lantus, and a $35 monthly cap for those with private insurance. Uninsured Americans are eligible for Sanofi’s Insulins Valyou Savings Program. President Joe Biden praised the move, and Eli Lilly and Novo Nordisk have also announced changes to how they price their insulin this month. The Inflation Reduction Act and the actions of the three major insulin makers are a step in the right direction to make insulin more accessible and affordable for people with diabetes.
Posts tagged as “Novo Nordisk”
Novo Nordisk, a Danish pharmaceutical firm, has announced that it will reduce the U.S. list price of some of its insulin products by up to 75%, effective January 1, 2024. This follows a similar move by Eli Lilly earlier this month, and is part of a larger effort to make insulin more affordable for people with diabetes. The price cuts are expected to provide relief to those who rely on insulin to manage their condition.